Bloomberg Markets & Finance via Youtube

Nov.08 — Fang Jianmin, co-founder and chief executive officer of RemeGen Co., discusses the Chinese biotechnology company’s initial public offering, strategy, and the drugs in its pipeline. RemeGen jumped more than 30 percent on its Hong Kong trading debut. Fang speaks with Juliette Saly and Rishaad Salamat on “Bloomberg Markets: Asia.”

READ ALSO  17 Education & Technology Group Files For U.S. IPO (Pending:YQ)